Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.
In an attempt to maximize the quality of life of advanced prostate cancer patients on prolonged total androgen ablation and to minimize side effects, we have devised a strategy of 'sequential androgen blockade'. Animal studies have demonstrated that the combination of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide was as effective as a luteinizing hormone-releasing hormone analog and flutamide in inhibiting the growth of the prostate. In a pilot trial, 10 potent patients with clinical stage C and D1 prostate cancer were given the combination of finasteride (5 mg b.i.d.) and flutamide (125-250 mg t.i.d.). Eight of ten men remained potent. At 3 months the mean prostate-specific antigen level of all patients was 3.8 ng/ml (34 ng/ml prior to therapy). In all patients serum testosterone increased and those with the highest increase demonstrated gynecomastia. The combination was easily tolerable and side effects were few. This treatment regime appears to offer the benefits of total androgen blockade, is less expensive and has fewer side effects. Further trials are warranted.
Fleshner
N E
NE
Division of Urology, Toronto Hospital, Ont., Canada.
Trachtenberg
J
J
D000368:Aged; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000139:chemically induced; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D005485:Flutamide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood
D013739:Testosterone; D018120:Finasteride; D005485:Flutamide; D007986:Luteinizing Hormone; D017430:Prostate-Specific Antigen